152818-52-5

Upstream product

• 170639-95-9 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo-3-isoquinolinecarboxamide 
• 170639-94-8 1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo-3-isoquinolinecarbonitrile 
• 170639-93-7 N-(cyanomethyl)-N-methyl-2-(2-methylbenzoyl)benzamide 
• 5469-51-2 methylbenzoyl-benzoic acid 

Downstream Products

• 1026397-73-8 2-Methyl-1-oxo-4-o-tolyl-1,2-dihydro-isoquinoline-3-carbonyl chloride 
• 159817-18-2 1,2-Dihydro-N-(2-methoxybenzyl)-2-methyl-4-(2-methylphenyl)-1-oxo-3-isoquinolinecarboxamide 
• 159817-05-7 N-[3,5-Bis(trifluoromethyl)benzyl]-1,2-dihydro-2-methyl-4-(2-methylphenyl)-1-oxo-3-isoquinolinecarboxamide 

Relevant academic research and scientific papers

Tachykinin receptor antagonists, isoquinolones and their production

Novel composition represented by the formula: STR1 wherein ring A and ring B each means a benzene ring which may be substituted; R means a hydrogen atom or an alkyl group which may be substituted; R1 means a hydrogen atom or an alkyl group which may be substituted; R2 means a hydrocarbon group which may be substituted or a heterocyclic group which may be substituted, or R1 and R2, taken together with the adjacent nitrogen atom, jointly form a ring which may be substituted, or a pharmaceutically acceptable salt thereof which is a useful tachykinin receptor antagonist.

Condensed heterocyclic compounds, their production and use

Novel compound represented by the formula: STR1 such as 6-Chloro-N-(2,6-diethoxyphenyl)-4-(2-methylphenyl-2-oxo-2H-1-benzopyran-3-acetamide: STR2 or a salt thereof. The compound has an excellent activity of inhibiting ACAT, lowering the cholesterol in blood and inhibiting tachykinin receptor. The present invention also relates to the production and use of the disclosed compound.

Novel, Potent, and Orally Active Substance P Antagonists: Synthesis and Antagonist Activity of N-Benzylcarboxamide Derivatives of Pyridopyridine

A series of 4-phenylisoquinolone derivatives were synthesized and evaluated for NK1 (substance P) antagonist activity.Highly potent antagonists, 4-phenyl-3-isoquinolone-N-benzylcarboxamides (11), were discovered from the structure-activity relationship studies on the isoquinolone-urea lead 1a.Optimization of the activity in this series resulted in the development of 5-phenyl-6-pyridopyridine-N-benzylcarboxamides (30) which are highly potent orally active NK1 antagonists.Among the compounds synthesized, N--7,8-dihydro-N,7-dimethyl-8-oxo-5-(substituted phenyl)-6-pyridopyridinecarboxamides (30a,f,g) showed excellent antagonist activities with IC50 values (in vitro inhibition of 125I>BH-SP binding in human IM-9-cells) of 0.21-0.34 nM and ED50 values (in vivo inhibition of capsaicin-induced plasma extravasation in guinea-pig trachea, iv) of 0.017-0.030 mg/kg.These compounds exhibited significantly potent activity upon oral adiministration with ED50 values of 0.068-0.17 mg/kg.Conformational studies on 30g indicated that the two stable conformers of 30g are quite similar to those of CP-99,994.